Renovo plc

Renovo plc is a biopharmaceutical company that was established in Manchester, United Kingdom in 1998. The company is primarily focused on the development and commercialization of drugs for the prevention and reduction of scarring in the skin and other organs.

History

Renovo was founded by Mark Ferguson and Sharon O'Kane, who were both professors at the University of Manchester. The company was initially funded by the Wellcome Trust and the North West Development Agency. In 2006, Renovo plc was listed on the London Stock Exchange.

Research and Development

Renovo's research and development efforts are primarily focused on the field of wound healing and scar prevention. The company's lead product, Juvista, is a recombinant human TGFβ2 intended for the prevention and reduction of scarring in the skin. Other products in development include Prevascar and Adaprev, which are also aimed at scar prevention and reduction.

Financial Performance

Renovo plc has faced financial challenges in the past. In 2011, the company announced that it would be discontinuing the development of Juvista following unsuccessful phase III clinical trials. This led to a significant drop in the company's share price and resulted in substantial job losses.

See Also

• Biopharmaceutical
• Wound healing
• Scar
• Transforming growth factor beta 2